Journals / Anadolu Psikiyatri Dergisi / 2018 / Cilt: 19 - Sayı: 5

Evaluation of sleep quality of early buprenorphine/naloxone treatment in opioid addicted patients

Buprenorfin/nalokson tedavisi gören opiyat bağımlısı hastalarda tedavinin erken döneminde uyku kalitesinin değerlendirilmesi

Pages
466–471
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We think that these findings can guide further research, as they show that opioid treat-ment does not only serve for addiction treatment but also for the treatment of the symptoms accompanying the opioid addiction. (Anatolian Journal of Psychiatry 2018; 19(5):466-471)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Opioid addiction is a chronic, relapsing and psychosocial disorder.
📊
Key Findings & Data:In opioid addiction patients, studies show that sleep disorders, deteriorated quality of sleep and sleep architecture changes might be seen.
💡
Conclusion & Impact:We think that these findings can guide further research, as they show that opioid treat-ment does not only serve for addiction treatment but also for the treatment of the symptoms accompanying the opioid addiction. (Anatolian Journal of Psychiatry 2018; 19(5):466-471)
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Opioid addiction is a chronic, relapsing and psychosocial disorder. In opioid addiction patients, studies show that sleep disorders, deteriorated quality of sleep and sleep architecture changes might be seen. In addition, comorbid psychiatric disorder and depression are frequently seen in opioid addicts. Comorbid psychiatric disorders and symptoms worsen of sleep quality in opioid addicts. This study aims to evaluate the quality of sleep during the periods of pre-treatment and in early opioid agonist maintenance treatment in the opioid addicts. Methods: The research included 29 patients in the Alcohol and Substance Addiction Treatment Unit of Trakya University Faculty of Medicine who have met diagnostic criteria for opioid addiction according to DSM-5, completed 28-day treatment, and admitted for control to Alcohol and Substance Addiction Treatment Unit after 1 month from discharge. The Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Pittsburgh Sleep Quality Index are administered to all the patients who participated to the study on the day 1, day 28, and in the month 2. All the patients were treated with buprenorphine and naloxone combination. Results: In our study, a time-dependent significant de-crease from day 1 to month 2 was determined in the average scores of the Pittsburgh Sleep Quality Index, which evaluates the sleep quality. In addition, the Pittsburgh Sleep Quality Index average scores showed differences in all time periods. Our study also determined a time -dependent significant decrease in the average scores of the Hamilton Depression Rating Scale and the Hamilton Anxiety Rating Scale, which evaluates respectively the depres-sive symptoms and anxiety symptoms on the day 0, day 28 and day 60. Discussion: In our research, we evaluated the sleep quality and the symptoms of depression and anxiety of the patients diagnosed with opioid addiction in pre-treatment and early period of opioid agonist maintenance treatment, and showed that those symptoms were getting better with treatment. We think that these findings can guide further research, as they show that opioid treat-ment does not only serve for addiction treatment but also for the treatment of the symptoms accompanying the opioid addiction. (Anatolian Journal of Psychiatry 2018; 19(5):466-471)

Özet

Amaç: Opiyat bağımlılığı kronik, yineleyici ve biyopsikososyal bir bozukluktur. Opiyat bağımlılarında uyku bozukluk-ları, uyku kalitesinde bozulma ve uyku yapısında farklılıklar görülebilmektedir. Buna ek olarak opiyat bağımlılarında depresyon ve diğer psikiyatrik bozukluk eş tanısı sık görülmektedir. Psikiyatrik belirtiler ve eş tanı bu hastalarda uyku kalitesini bozmaktadır. Bu çalışmada opiyat bağımlılığı olan hastalarda tedavi öncesi, opiyattan arındırma ve opiyat parsiyel agonist idame tedavisi süresince uyku kalitelerinin değerlendirilmesi amaçlanmıştır. Yöntem: Araş-tırmaya DSM-5 ölçütlerine göre opiyat kullanım bozukluğu tanı ölçütlerini karşılayan, 28 günlük tedavi programını tamamlayan ve taburculuk sonrası birinci ayda AMATEM polikliniğine izleme kontrolüne gelen 29 hasta alınmıştır. Araştırma katılan tüm hastalara 1. gün, 28. gün ve 2. ayda Hamilton Depresyon Derecelendirme Ölçeği, Hamilton Anksiyete Değerlendirme Ölçeği, Pittsburgh Uyku Kalitesi Ölçeği uygulanmıştır. Hastaların hepsi buprenorfin/nalok-son kombinasyonu ile tedavi edilmişlerdir. Sonuçlar: Araştırmamızda 1. gün, 28. gün ve 2. ayda uyku kalitelerinin anlamlı olarak düzeldiği ve uykusuzluğun azaldığı; ayrıca 1. gün, 28. gün ve 2. ayda depresif ve anksiyete belirtile-rinde zamana göre anlamlı bir düşüş olduğu bulunmuştur. Tartışma: Araştırmamızda opiyat bağımlılığı hastala-rında uyku kalitesi, depresif ve anksiyete belirtilerinin tedavi öncesi ve opiyat parsiyel agonist tedavisinin erken dönemi süresince düzelme gösterdiği saptanmıştır. Bu bulgular opiyat bağımlılarında bağımlılık ile beraber, uyku-suzluk gibi eşlik eden ruhsal belirtilerin de tedavi ile düzeldiğini göstermiştir. (Anadolu Psikiyatri Derg 2018; 19(5):466-471)

🔖

Cite This Article

ŞİPKA, H., VARDAR, E. (2018). Evaluation of sleep quality of early buprenorphine/naloxone treatment in opioid addicted patients. Anadolu Psikiyatri Dergisi, Cilt: 19 - Sayı: 5, 466–471. https://ajindex.com/articles/355738

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Croissant B, Klein O, Gehrlein L, Kniest A, Her-mann D, Diehl K. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry 2006
  2. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance de-pendence disorders. J Psychiatry Neurosci 2004
  3. Pinkofsky HB, Hahn AM, Campbell FA, Rueda J, Daley DC, Douaihy AB. Reduction of opioid-withdrawal symptoms with quetiapine. Clin Psychiatry 2005
  4. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. Affective Disord 1997
  5. Wetherell JL, Roux H Le, Margaret G. DSM-IV criteria for generalized anxiety disorder in older adults: Distinguishing the worried from the well. Psychology and Aging 2003
  6. Kosten TA, Bianchi MS, Kosten TR. The predictive validity of the dependence syndrome in opiate abusers. Am J Drug Alcohol Abuse 1992
  7. Kahan M, Srivastava A, Ordean A, Buprenor-phine: new treatment of opioid addiction in primary care. Can Fam Physician 2011
  8. Asaad TA, Ghanem MH, Abdel Samee AM, El-habiby MM. Sleep profile in patients with chronic opioid abuse: A polysomnographic evaluation in an Egyptian sample. Addict Disord Their Treat 2011
  9. Howe RC, Hegge FW, Phillips JL. Acute heroin abstinence in man: Changes in behavior and sleep. Drug Alcohol Depend 1980
  10. Kay D, Pickworth W, Neidert GL. Morphine-like insomnia from heroin in nondependent human addicts. Br J Clin Pharmac 1981
  11. Ağargün MY, Kara H, Anlar Ö. Pittsburgh Uyku Kalitesi İndeksinin geçerliliği ve güvenirliği. Türk Psikiyatr Derg 1996
  12. Yazıcı MK, Demir B, Tanrıverdi N, Karaağaoğlu E,Yolaç P. Hamilton Anksiyete Değerlendirme Ölçeği, derecelendiriciler arası güvenilirlik ve geçerlilik çalışması. Türk Psikiyatr Derg 1998
  13. Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan N. Hamilton Depresyon Derecelendirme ölçeğinin geçerliği, güvenirliği ve klinik kullanımı. 3P Derg 1996
  14. Cronin A, Keifer JC, Baghdoyan HA, Lydic R. Opioid inhibition of rapid eye movement sleep by a specific mu receptor agonist. Br J Anaesth 1995
  15. Gauthier EA, Guzick SE, Brummett CM, Bagh-doyan HA, Lydic R. Buprenorphine disrupts sleep and decreases adenosine concentrations in sleep-regulating brain reg